Рациональная фармакотерапия в кардиологии (Jan 2016)

HEART FAILURE, DIABETES, BETA-BLOCKERS AND RISK OF HYPOGLYCEMIA

  • A. A. Aleksandrov,
  • O. А. Shatskaya,
  • S. S. Kuharenko,
  • E. N. Drozdova,
  • I. Z. Bondarenko,
  • N. D. Tabidze,
  • M. V. Shestakova

DOI
https://doi.org/10.20996/1819-6446-2008-4-3-47-51
Journal volume & issue
Vol. 4, no. 3
pp. 47 – 51

Abstract

Read online

Aim. To evaluate an influence of carvedilol on risk of hypoglycemia in patients with diabetes type 2 (D2) and chronic heart failure (CHF) treated with angiotensin converting enzyme (ACE) inhibitors.Material and methods. 13 patients (10 men, 3 women; aged 59,8±6,7 y.o.) with D2 and CHF caused by ischemic heart disease were included in the study. Before inclusion all patients were treated with ACE inhibitors and various beta-blockers (atenolol, metoprolol, bisoprolol). These beta-blockers were changed for carvedilol. Heart ultrasonography, blood pressure control, glycemia monitoring, HbA1c level determination were performed before, during and after carvedilol therapy.Results. Carvedilol reduces frequency and duration of hypoglycaemia episodes. There were not episodes of severe hypoglycaemia during carvedilol therapy.Conclusion. Carvedilol reduces risk of hypoglycemia when it is used in combination with ACE inhiditors in diabetic patients with CHF.

Keywords